French pharmaceutical company Ipsen has agreed to acquire Swiss biotech firm Memo in a transaction that could exceed $800 million, marking its second major deal announcement this week. The acquisition follows Ipsen's recent agreement to take over Kartos Therapeutics, another biotechnology company in its expanding portfolio.

This back-to-back dealmaking suggests Ipsen is aggressively pursuing growth through strategic acquisitions. The company appears focused on strengthening its position in the biotech sector, with Memo representing the latest addition to its pipeline expansion efforts. Both targets operate in the pharmaceutical development space, indicating Ipsen's commitment to building therapeutic capabilities.

The rapid succession of acquisitions signals confidence from Ipsen's leadership in pursuing external growth opportunities. For investors, this demonstrates active portfolio management and a willingness to deploy capital for strategic assets. The deals also reflect ongoing consolidation trends in the biotechnology industry.

The acquisitions position Ipsen to compete more effectively in the global pharmaceutical market while diversifying its research and development pipeline across multiple therapeutic areas.